About our clinical trials
Thrombomodulin alfa (ART-123) is currently being studied in patients with severe sepsis and coagulopathy in a global phase 3 randomized placebo controlled safety and efficacy study entitled the SCARLET study. Patients enrolled in this study must be receiving treatment in an intensive care setting for sepsis with a bacterial source and have an associated organ dysfunction and blood clotting abnormality (coagulopathy) caused by the sepsis. The most common sources of infection are the lung, abdomen, urinary tract, and blood. The link to the study on the clinicatrials.gov website is shown below.